TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Trial of Liaison Psychiatry in Primary Care
Brief Summary: This study will evaluate the effectiveness of a nurse-led case management intervention in improving disease control and depression symptoms in adults with diabetes and/or heart disease who are also depressed.


Options:
A: Arm Label: Arm 1; Type: OTHER; Interventions: Procedure: System level depression care quality improvement | Intervention Type: PROCEDURE; Name: System level depression care quality improvement; Assigned to Arm(s): Arm 1
B: Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Treatment as usual | Arm Label: A; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse-led case management | Intervention Type: BEHAVIORAL; Name: Nurse-led case management; Assigned to Arm(s): A | Intervention Type: BEHAVIORAL; Name: Treatment as usual; Assigned to Arm(s): B
C: Arm Label: ICC; Type: EXPERIMENTAL; Interventions: Other: Integrated collaborative care | Arm Label: E&R; Type: ACTIVE_COMPARATOR; Interventions: Other: Education and Resources | Intervention Type: OTHER; Name: Integrated collaborative care; Assigned to Arm(s): ICC | Intervention Type: OTHER; Name: Education and Resources; Assigned to Arm(s): E&R
D: Arm Label: Arm 1 Telemedicine Outreach for PTSD; Type: EXPERIMENTAL; Interventions: Other: Telemedicine Outreach for PTSD | Arm Label: Arm 2 Treatment as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Telemedicine Outreach for PTSD; Assigned to Arm(s): Arm 1 Telemedicine Outreach for PTSD

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Trial of Liaison Psychiatry in Primary Care
Brief Summary: This study will evaluate the effectiveness of a nurse-led case management intervention in improving disease control and depression symptoms in adults with diabetes and/or heart disease who are also depressed.


Options:
A: Arm Label: Group Clinic; Type: EXPERIMENTAL; Interventions: Behavioral: Improving outcomes using group clinics for older patients | Arm Label: Uusual Care; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Standard of Care | Intervention Type: BEHAVIORAL; Name: Improving outcomes using group clinics for older patients; Assigned to Arm(s): Group Clinic | Intervention Type: BEHAVIORAL; Name: Standard of Care; Assigned to Arm(s): Uusual Care
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Interactive Voice Response System | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse-Led Group Clinic Visits | Intervention Type: BEHAVIORAL; Name: Interactive Voice Response System; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Nurse-Led Group Clinic Visits; Assigned to Arm(s): 2
C: Arm Label: Health coaching; Type: EXPERIMENTAL; Interventions: Behavioral: Health coaching | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual care | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): Usual care | Intervention Type: BEHAVIORAL; Name: Health coaching; Assigned to Arm(s): Health coaching
D: Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Treatment as usual | Arm Label: A; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse-led case management | Intervention Type: BEHAVIORAL; Name: Nurse-led case management; Assigned to Arm(s): A | Intervention Type: BEHAVIORAL; Name: Treatment as usual; Assigned to Arm(s): B

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Trial of Liaison Psychiatry in Primary Care
Brief Summary: This study will evaluate the effectiveness of a nurse-led case management intervention in improving disease control and depression symptoms in adults with diabetes and/or heart disease who are also depressed.


Options:
A: Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: Reverse Colocated Integrated Care | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care | Intervention Type: BEHAVIORAL; Name: Reverse Colocated Integrated Care; Assigned to Arm(s): Intervention Group | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): Control Group
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Collaborative depression care management | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Enhanced usual care | Intervention Type: BEHAVIORAL; Name: Collaborative depression care management; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Enhanced usual care; Assigned to Arm(s): 2
C: Arm Label: Collaborative Care for Mental Health Disorders; Type: ACTIVE_COMPARATOR; Interventions: Other: Collaborative Care for Mental Health Disorders | Arm Label: Collaborative Care for Opioid Use Disorder; Type: EXPERIMENTAL; Interventions: Other: Collaborative Care for Mental Health Disorders, Other: Collaborative Care for Opioid Use Disorder | Intervention Type: OTHER; Name: Collaborative Care for Mental Health Disorders; Assigned to Arm(s): Collaborative Care for Mental Health Disorders, Collaborative Care for Opioid Use Disorder | Intervention Type: OTHER; Name: Collaborative Care for Opioid Use Disorder; Assigned to Arm(s): Collaborative Care for Opioid Use Disorder
D: Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Treatment as usual | Arm Label: A; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse-led case management | Intervention Type: BEHAVIORAL; Name: Nurse-led case management; Assigned to Arm(s): A | Intervention Type: BEHAVIORAL; Name: Treatment as usual; Assigned to Arm(s): B

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Trial of Liaison Psychiatry in Primary Care
Brief Summary: This study will evaluate the effectiveness of a nurse-led case management intervention in improving disease control and depression symptoms in adults with diabetes and/or heart disease who are also depressed.


Options:
A: Arm Label: Exercise group; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise group | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise group; Assigned to Arm(s): Exercise group
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Premier Lifestyle Intervention with DASH Diet | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Premier Lifestyle Intervention with DASH Diet; Assigned to Arm(s): 1
C: Arm Label: Enhanced Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Staged Care Management; Type: EXPERIMENTAL; Interventions: Behavioral: Medication Care Management (MCM), Behavioral: Cognitive-Behavioral Therapy (CBT) | Intervention Type: BEHAVIORAL; Name: Medication Care Management (MCM); Assigned to Arm(s): Staged Care Management | Intervention Type: BEHAVIORAL; Name: Cognitive-Behavioral Therapy (CBT); Assigned to Arm(s): Staged Care Management
D: Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Treatment as usual | Arm Label: A; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse-led case management | Intervention Type: BEHAVIORAL; Name: Nurse-led case management; Assigned to Arm(s): A | Intervention Type: BEHAVIORAL; Name: Treatment as usual; Assigned to Arm(s): B

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind Study to Compare the Safety and Efficacy of PAR-101 to Vancomycin in Subjects With Clostridium Difficile-Associated Diarrhea (CDAD)
Brief Summary: This is a comparative study to investigate the safety and efficacy of PAR-101/OPT-80 (fidaxomicin) versus vancomycin in subjects with Clostridium difficile-associated diarrhea (CDAD).


Options:
A: Arm Label: Probiotic; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Probiotic | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Probiotic; Assigned to Arm(s): Probiotic | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Cadazolid 250 mg; Type: EXPERIMENTAL; Interventions: Drug: Cadazolid, Drug: Placebo-matching vancomycin | Arm Label: Cadazolid 500 mg; Type: EXPERIMENTAL; Interventions: Drug: Cadazolid, Drug: Placebo-matching vancomycin | Arm Label: Cadazolid 1000 mg; Type: EXPERIMENTAL; Interventions: Drug: Cadazolid, Drug: Placebo-matching vancomycin | Arm Label: Vancomycin 125 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vancomycin, Drug: Placebo-matching cadazolid | Intervention Type: DRUG; Name: Cadazolid; Assigned to Arm(s): Cadazolid 1000 mg, Cadazolid 250 mg, Cadazolid 500 mg | Intervention Type: DRUG; Name: Vancomycin; Assigned to Arm(s): Vancomycin 125 mg | Intervention Type: DRUG; Name: Placebo-matching cadazolid; Assigned to Arm(s): Vancomycin 125 mg | Intervention Type: DRUG; Name: Placebo-matching vancomycin; Assigned to Arm(s): Cadazolid 1000 mg, Cadazolid 250 mg, Cadazolid 500 mg
C: Arm Label: LFF571 (POC); Type: EXPERIMENTAL; Interventions: Drug: LFF571 | Arm Label: Vancomycin (POC); Type: ACTIVE_COMPARATOR; Interventions: Drug: Vancomycin (POC) | Arm Label: LFF571 Dose level 1 (cohort 2); Type: EXPERIMENTAL; Interventions: Drug: LFF571 | Arm Label: LFF571 Dose level 2 (cohort 2); Type: EXPERIMENTAL; Interventions: Drug: LFF571 | Arm Label: LFF571 Dose level 3 (cohort 2); Type: EXPERIMENTAL; Interventions: Drug: LFF571 | Arm Label: LFF571 Dose level 4 (cohort 2); Type: EXPERIMENTAL; Interventions: Drug: LFF571 | Intervention Type: DRUG; Name: LFF571; Assigned to Arm(s): LFF571 (POC), LFF571 Dose level 1 (cohort 2), LFF571 Dose level 2 (cohort 2), LFF571 Dose level 3 (cohort 2), LFF571 Dose level 4 (cohort 2) | Intervention Type: DRUG; Name: Vancomycin (POC); Assigned to Arm(s): Vancomycin (POC)
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vancomycin | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: PAR-101/OPT-80 | Intervention Type: DRUG; Name: PAR-101/OPT-80; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Vancomycin; Assigned to Arm(s): 1

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Controlled Study to Evaluate the Safety and Efficacy of an Intravitreal Fluocinolone Acetonide (0.5mg) Implant Compared to Standardized Therapy in Subjects With Non-Infectious Uveitis Affecting the Posterior Segment of the Eye
Brief Summary: This is a 3 year,superiority, multicenter, open-label, randomised controlled safety and efficacy study. The aim of this study is to evaluate the effect of an intravitreal fluocinolone acetonide (0.59 mg) implant compared to standardized therapy in subjects with unilateral or bilateral, non-infectious uveitis affecting the posterior segment of the eye.


Options:
A: Intervention Type: DRUG; Name: DEX PS DDS®; Assigned to Arm(s): N/A
B: Arm Label: Fluocinolone acetonide 0.59mg; Type: EXPERIMENTAL; Interventions: Drug: fluocinolone acetonide intravitreal implant | Arm Label: Fluocinolone acetonide 2.1mg; Type: EXPERIMENTAL; Interventions: Drug: Fluocinolone acetonide 2.1mg | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: fluocinolone acetonide intravitreal implant; Assigned to Arm(s): Fluocinolone acetonide 0.59mg | Intervention Type: DRUG; Name: Fluocinolone acetonide 2.1mg; Assigned to Arm(s): Fluocinolone acetonide 2.1mg
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexamethasone | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: dexamethasone | Arm Label: 3; Type: SHAM_COMPARATOR; Interventions: Drug: Sham injection | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: dexamethasone; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Sham injection; Assigned to Arm(s): 3
D: Arm Label: Fluocinolone acetonide; Type: EXPERIMENTAL; Interventions: Drug: fluocinolone acetonide intravitreal implant | Arm Label: Standard care; Type: ACTIVE_COMPARATOR; Interventions: Drug: corticosteroids and immunosuppressants | Intervention Type: DRUG; Name: fluocinolone acetonide intravitreal implant; Assigned to Arm(s): Fluocinolone acetonide | Intervention Type: DRUG; Name: corticosteroids and immunosuppressants; Assigned to Arm(s): Standard care

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Controlled Study to Evaluate the Safety and Efficacy of an Intravitreal Fluocinolone Acetonide (0.5mg) Implant Compared to Standardized Therapy in Subjects With Non-Infectious Uveitis Affecting the Posterior Segment of the Eye
Brief Summary: This is a 3 year,superiority, multicenter, open-label, randomised controlled safety and efficacy study. The aim of this study is to evaluate the effect of an intravitreal fluocinolone acetonide (0.59 mg) implant compared to standardized therapy in subjects with unilateral or bilateral, non-infectious uveitis affecting the posterior segment of the eye.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexamethasone | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: dexamethasone | Arm Label: 3; Type: SHAM_COMPARATOR; Interventions: Drug: Sham injection | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: dexamethasone; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Sham injection; Assigned to Arm(s): 3
B: Arm Label: Fluocinolone acetonide; Type: EXPERIMENTAL; Interventions: Drug: fluocinolone acetonide intravitreal implant | Arm Label: Standard care; Type: ACTIVE_COMPARATOR; Interventions: Drug: corticosteroids and immunosuppressants | Intervention Type: DRUG; Name: fluocinolone acetonide intravitreal implant; Assigned to Arm(s): Fluocinolone acetonide | Intervention Type: DRUG; Name: corticosteroids and immunosuppressants; Assigned to Arm(s): Standard care
C: Intervention Type: DRUG; Name: DEX PS DDS®; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluocinolone acetonide intraocular implant | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: oral corticosteroid with immunosuppressive agents as needed | Intervention Type: DRUG; Name: fluocinolone acetonide intraocular implant; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: oral corticosteroid with immunosuppressive agents as needed; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Controlled Study to Evaluate the Safety and Efficacy of an Intravitreal Fluocinolone Acetonide (0.5mg) Implant Compared to Standardized Therapy in Subjects With Non-Infectious Uveitis Affecting the Posterior Segment of the Eye
Brief Summary: This is a 3 year,superiority, multicenter, open-label, randomised controlled safety and efficacy study. The aim of this study is to evaluate the effect of an intravitreal fluocinolone acetonide (0.59 mg) implant compared to standardized therapy in subjects with unilateral or bilateral, non-infectious uveitis affecting the posterior segment of the eye.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluocinolone acetonide intraocular implant | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: oral corticosteroid with immunosuppressive agents as needed | Intervention Type: DRUG; Name: fluocinolone acetonide intraocular implant; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: oral corticosteroid with immunosuppressive agents as needed; Assigned to Arm(s): 2
B: Arm Label: Fluocinolone acetonide; Type: EXPERIMENTAL; Interventions: Drug: fluocinolone acetonide intravitreal implant | Arm Label: Standard care; Type: ACTIVE_COMPARATOR; Interventions: Drug: corticosteroids and immunosuppressants | Intervention Type: DRUG; Name: fluocinolone acetonide intravitreal implant; Assigned to Arm(s): Fluocinolone acetonide | Intervention Type: DRUG; Name: corticosteroids and immunosuppressants; Assigned to Arm(s): Standard care
C: Intervention Type: DRUG; Name: DEX PS DDS®; Assigned to Arm(s): N/A
D: Arm Label: Fluocinolone acetonide 0.59mg; Type: EXPERIMENTAL; Interventions: Drug: fluocinolone acetonide intravitreal implant | Arm Label: Fluocinolone acetonide 2.1mg; Type: EXPERIMENTAL; Interventions: Drug: Fluocinolone acetonide 2.1mg | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: fluocinolone acetonide intravitreal implant; Assigned to Arm(s): Fluocinolone acetonide 0.59mg | Intervention Type: DRUG; Name: Fluocinolone acetonide 2.1mg; Assigned to Arm(s): Fluocinolone acetonide 2.1mg

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Heart Outcomes Prevention Evaluation-3
Brief Summary: Heart disease and stroke are major causes of death and disability worldwide and are largely preventable. Cholesterol and blood pressure are major cardiovascular risk factors. Previous studies have shown that certain drugs can effectively and safely lower cholesterol and blood pressure and prevent heart attacks and strokes. Such studies have been conducted primarily in people who had already sustained a heart attack or a stroke, or in people with high cholesterol and blood pressure levels. However, most heart attacks and strokes occur in people with average ("normal") cholesterol and blood pressure. Therefore, in the HOPE-3 trial the investigators will evaluate whether a cholesterol lowering drug, rosuvastatin, and a combination blood pressure lowering pill, candesartan/hydrochlorothiazide, used alone or together can reduce the risk of heart attacks, stroke and their sequelae in people without known heart disease and at average risk.


Options:
A: Arm Label: Rosuvastatin; Type: PLACEBO_COMPARATOR; Interventions: Drug: Rosuvastatin | Arm Label: Candesartan/HCT; Type: PLACEBO_COMPARATOR; Interventions: Drug: Candesartan/HCT | Intervention Type: DRUG; Name: Candesartan/HCT; Assigned to Arm(s): Candesartan/HCT | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): Rosuvastatin
B: Arm Label: Intensive; Type: EXPERIMENTAL; Interventions: Other: Anti-hypertensive therapy to SBP 130 mm Hg | Arm Label: Standard; Type: ACTIVE_COMPARATOR; Interventions: Other: Anti-hypertensive therapy to SBP 145 mm Hg | Intervention Type: OTHER; Name: Anti-hypertensive therapy to SBP 130 mm Hg; Assigned to Arm(s): Intensive | Intervention Type: OTHER; Name: Anti-hypertensive therapy to SBP 145 mm Hg; Assigned to Arm(s): Standard
C: Arm Label: Intensive Control of SBP; Type: EXPERIMENTAL; Interventions: Drug: Intensive control of SBP | Arm Label: Standard Control of SBP; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard control of SBP | Intervention Type: DRUG; Name: Intensive control of SBP; Assigned to Arm(s): Intensive Control of SBP | Intervention Type: DRUG; Name: Standard control of SBP; Assigned to Arm(s): Standard Control of SBP
D: Arm Label: Lifestyle Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle Intervention | Arm Label: Diabetes Support and Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Diabetes Support and Education | Intervention Type: BEHAVIORAL; Name: Lifestyle Intervention; Assigned to Arm(s): Lifestyle Intervention | Intervention Type: BEHAVIORAL; Name: Diabetes Support and Education; Assigned to Arm(s): Diabetes Support and Education

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Heart Outcomes Prevention Evaluation-3
Brief Summary: Heart disease and stroke are major causes of death and disability worldwide and are largely preventable. Cholesterol and blood pressure are major cardiovascular risk factors. Previous studies have shown that certain drugs can effectively and safely lower cholesterol and blood pressure and prevent heart attacks and strokes. Such studies have been conducted primarily in people who had already sustained a heart attack or a stroke, or in people with high cholesterol and blood pressure levels. However, most heart attacks and strokes occur in people with average ("normal") cholesterol and blood pressure. Therefore, in the HOPE-3 trial the investigators will evaluate whether a cholesterol lowering drug, rosuvastatin, and a combination blood pressure lowering pill, candesartan/hydrochlorothiazide, used alone or together can reduce the risk of heart attacks, stroke and their sequelae in people without known heart disease and at average risk.


Options:
A: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: chlortalidone-amiloride; Type: EXPERIMENTAL; Interventions: Drug: Chlorthalidone plus amiloride | Intervention Type: DRUG; Name: Chlorthalidone plus amiloride; Assigned to Arm(s): chlortalidone-amiloride | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
B: Intervention Type: DRUG; Name: Telmisartan; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Combination of Telmisartan and Ramipril; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Ramipril; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: valsartan; Assigned to Arm(s): N/A
D: Arm Label: Rosuvastatin; Type: PLACEBO_COMPARATOR; Interventions: Drug: Rosuvastatin | Arm Label: Candesartan/HCT; Type: PLACEBO_COMPARATOR; Interventions: Drug: Candesartan/HCT | Intervention Type: DRUG; Name: Candesartan/HCT; Assigned to Arm(s): Candesartan/HCT | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): Rosuvastatin

Answer: D